APO Research
Talk to an analyst

APO RESEARCH · REPORT

Genetic Engineering Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Genetic Engineering Drug Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchGenetic Engineering Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic Engineering Drug Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Genetic Engineering Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic Engineering Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic Engineering Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Genetic Engineering Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Genetic Engineering Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Genetic Engineering Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genetic Engineering Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Genetic Engineering Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Genetic Engineering Drug market include Tonghua Dongbao Pharmaceutical, Shenzhen Neptunus Interlong Bio-Technique, Shanghai Lansheng Guojian Pharmaceutical, Jiangsu Sihuan Bioengineering, Anhui Anke Biotechnology, GeneScience Pharmaceuticals, Biotech Pharmaceutical, Beijing SL Pharmaceutical and 3SBio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Genetic Engineering Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Genetic Engineering Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Genetic Engineering Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Genetic Engineering Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Genetic Engineering Drug Segment by Company

Tonghua Dongbao Pharmaceutical

Shenzhen Neptunus Interlong Bio-Technique

Shanghai Lansheng Guojian Pharmaceutical

Jiangsu Sihuan Bioengineering

Anhui Anke Biotechnology

GeneScience Pharmaceuticals

Biotech Pharmaceutical

Beijing SL Pharmaceutical

3SBio

Genetic Engineering Drug Segment by Type

Recombinant Human Insulin

Recombinant Human Growth Hormone

Recombinant Human Interferon

Recombinant Human Erythropoietin

Monoclonal Antibody

Genetic Engineering Drug Segment by Application

Medicine

Research

Agriculture

Industrial

Other

Genetic Engineering Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Genetic Engineering Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Genetic Engineering Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Genetic Engineering Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Genetic Engineering Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Engineering Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic Engineering Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Engineering Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Genetic Engineering Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Genetic Engineering Drug industry.

Chapter 3: Detailed analysis of Genetic Engineering Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Genetic Engineering Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Genetic Engineering Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Genetic Engineering Drug Industry Trends Table 2. Genetic Engineering Drug Industry Drivers Table 3. Genetic Engineering Drug Industry Opportunities and Challenges Table 4. Genetic Engineering Drug Industry Restraints Table 5. Global Genetic Engineering Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Genetic Engineering Drug Revenue Share by Company (2021-2026) Table 7. Global Genetic Engineering Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Genetic Engineering Drug Sales Volume Share by Company (2021-2026) Table 9. Global Genetic Engineering Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Genetic Engineering Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Genetic Engineering Drug Key Company Manufacturing Base & Headquarters Table 12. Global Genetic Engineering Drug Company, Product Type & Application Table 13. Global Genetic Engineering Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Genetic Engineering Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Human Insulin Table 18. Significant Companies of Recombinant Human Growth Hormone Table 19. Significant Companies of Recombinant Human Interferon Table 20. Significant Companies of Recombinant Human Erythropoietin Table 21. Significant Companies of Monoclonal Antibody Table 22. Global Genetic Engineering Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Genetic Engineering Drug Sales Volume by Type (2021-2026) & (k units) Table 24. Global Genetic Engineering Drug Sales Volume by Type (2027-2032) & (k units) Table 25. Global Genetic Engineering Drug Sales Volume Share by Type (2021-2026) Table 26. Global Genetic Engineering Drug Sales Volume Share by Type (2027-2032) Table 27. Global Genetic Engineering Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Genetic Engineering Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Genetic Engineering Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Genetic Engineering Drug Sales Value Share by Type (2021-2026) Table 31. Global Genetic Engineering Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Medicine Table 33. Significant Companies of Research Table 34. Significant Companies of Agriculture Table 35. Significant Companies of Industrial Table 36. Significant Companies of Other Table 37. Global Genetic Engineering Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Genetic Engineering Drug Sales Volume by Application (2021-2026) & (k units) Table 39. Global Genetic Engineering Drug Sales Volume by Application (2027-2032) & (k units) Table 40. Global Genetic Engineering Drug Sales Volume Share by Application (2021-2026) Table 41. Global Genetic Engineering Drug Sales Volume Share by Application (2027-2032) Table 42. Global Genetic Engineering Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Genetic Engineering Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Genetic Engineering Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Genetic Engineering Drug Sales Value Share by Application (2021-2026) Table 46. Global Genetic Engineering Drug Sales Value Share by Application (2027-2032) Table 47. Global Genetic Engineering Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Genetic Engineering Drug Sales by Region (2021-2026) & (k units) Table 49. Global Genetic Engineering Drug Sales Market Share by Region (2021-2026) Table 50. Global Genetic Engineering Drug Sales by Region (2027-2032) & (k units) Table 51. Global Genetic Engineering Drug Sales Market Share by Region (2027-2032) Table 52. Global Genetic Engineering Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Genetic Engineering Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Genetic Engineering Drug Sales Value Share by Region (2021-2026) Table 55. Global Genetic Engineering Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Genetic Engineering Drug Sales Value Share by Region (2027-2032) Table 57. Global Genetic Engineering Drug Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Genetic Engineering Drug Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Genetic Engineering Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Genetic Engineering Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Genetic Engineering Drug Sales by Country (2021-2026) & (k units) Table 62. Global Genetic Engineering Drug Sales Market Share by Country (2021-2026) Table 63. Global Genetic Engineering Drug Sales by Country (2027-2032) & (k units) Table 64. Global Genetic Engineering Drug Sales Market Share by Country (2027-2032) Table 65. Global Genetic Engineering Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Genetic Engineering Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Genetic Engineering Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Genetic Engineering Drug Sales Value Market Share by Country (2027-2032) Table 69. Tonghua Dongbao Pharmaceutical Company Information Table 70. Tonghua Dongbao Pharmaceutical Business Overview Table 71. Tonghua Dongbao Pharmaceutical Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Tonghua Dongbao Pharmaceutical Genetic Engineering Drug Product Portfolio Table 73. Tonghua Dongbao Pharmaceutical Recent Development Table 74. Shenzhen Neptunus Interlong Bio-Technique Company Information Table 75. Shenzhen Neptunus Interlong Bio-Technique Business Overview Table 76. Shenzhen Neptunus Interlong Bio-Technique Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Shenzhen Neptunus Interlong Bio-Technique Genetic Engineering Drug Product Portfolio Table 78. Shenzhen Neptunus Interlong Bio-Technique Recent Development Table 79. Shanghai Lansheng Guojian Pharmaceutical Company Information Table 80. Shanghai Lansheng Guojian Pharmaceutical Business Overview Table 81. Shanghai Lansheng Guojian Pharmaceutical Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Shanghai Lansheng Guojian Pharmaceutical Genetic Engineering Drug Product Portfolio Table 83. Shanghai Lansheng Guojian Pharmaceutical Recent Development Table 84. Jiangsu Sihuan Bioengineering Company Information Table 85. Jiangsu Sihuan Bioengineering Business Overview Table 86. Jiangsu Sihuan Bioengineering Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Jiangsu Sihuan Bioengineering Genetic Engineering Drug Product Portfolio Table 88. Jiangsu Sihuan Bioengineering Recent Development Table 89. Anhui Anke Biotechnology Company Information Table 90. Anhui Anke Biotechnology Business Overview Table 91. Anhui Anke Biotechnology Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Anhui Anke Biotechnology Genetic Engineering Drug Product Portfolio Table 93. Anhui Anke Biotechnology Recent Development Table 94. GeneScience Pharmaceuticals Company Information Table 95. GeneScience Pharmaceuticals Business Overview Table 96. GeneScience Pharmaceuticals Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. GeneScience Pharmaceuticals Genetic Engineering Drug Product Portfolio Table 98. GeneScience Pharmaceuticals Recent Development Table 99. Biotech Pharmaceutical Company Information Table 100. Biotech Pharmaceutical Business Overview Table 101. Biotech Pharmaceutical Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Biotech Pharmaceutical Genetic Engineering Drug Product Portfolio Table 103. Biotech Pharmaceutical Recent Development Table 104. Beijing SL Pharmaceutical Company Information Table 105. Beijing SL Pharmaceutical Business Overview Table 106. Beijing SL Pharmaceutical Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Beijing SL Pharmaceutical Genetic Engineering Drug Product Portfolio Table 108. Beijing SL Pharmaceutical Recent Development Table 109. 3SBio Company Information Table 110. 3SBio Business Overview Table 111. 3SBio Genetic Engineering Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. 3SBio Genetic Engineering Drug Product Portfolio Table 113. 3SBio Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Genetic Engineering Drug Distributors List Table 117. Genetic Engineering Drug Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Genetic Engineering Drug Product Image Figure 2. Global Genetic Engineering Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic Engineering Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Genetic Engineering Drug Sales (2021-2032) & (k units) Figure 5. Global Genetic Engineering Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Genetic Engineering Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Human Insulin Image Figure 10. Recombinant Human Growth Hormone Image Figure 11. Recombinant Human Interferon Image Figure 12. Recombinant Human Erythropoietin Image Figure 13. Monoclonal Antibody Image Figure 14. Global Genetic Engineering Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Genetic Engineering Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Genetic Engineering Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Genetic Engineering Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Genetic Engineering Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Genetic Engineering Drug Sales Value Share by Type (2021-2032) Figure 20. Medicine Image Figure 21. Research Image Figure 22. Agriculture Image Figure 23. Industrial Image Figure 24. Other Image Figure 25. Global Genetic Engineering Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Genetic Engineering Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Genetic Engineering Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Genetic Engineering Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Genetic Engineering Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Genetic Engineering Drug Sales Value Share by Application (2021-2032) Figure 31. Global Genetic Engineering Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Genetic Engineering Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Genetic Engineering Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Genetic Engineering Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Genetic Engineering Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Genetic Engineering Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Genetic Engineering Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Genetic Engineering Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Genetic Engineering Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Genetic Engineering Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Genetic Engineering Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Genetic Engineering Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Genetic Engineering Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Genetic Engineering Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Genetic Engineering Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Genetic Engineering Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Genetic Engineering Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Human Insulin
  • Recombinant Human Growth Hormone
  • Recombinant Human Interferon
  • Recombinant Human Erythropoietin
  • Monoclonal Antibody
Applications
  • Medicine
  • Research
  • Agriculture
  • Industrial
  • Other
Companies covered
  • Tonghua Dongbao Pharmaceutical
  • Shenzhen Neptunus Interlong Bio-Technique
  • Shanghai Lansheng Guojian Pharmaceutical
  • Jiangsu Sihuan Bioengineering
  • Anhui Anke Biotechnology
  • GeneScience Pharmaceuticals
  • Biotech Pharmaceutical
  • Beijing SL Pharmaceutical
  • 3SBio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Genetic Engineering Drug Sales Value (2021-2032)
  4. 1.2.2 Global Genetic Engineering Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Genetic Engineering Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Genetic Engineering Drug Market Dynamics
  1. 2.1 Genetic Engineering Drug Industry Trends
  2. 2.2 Genetic Engineering Drug Industry Drivers
  3. 2.3 Genetic Engineering Drug Industry Opportunities and Challenges
  4. 2.4 Genetic Engineering Drug Industry Restraints
3 Genetic Engineering Drug Market by Company
  1. 3.1 Global Genetic Engineering Drug Company Revenue Ranking in 2025
  2. 3.2 Global Genetic Engineering Drug Revenue by Company (2021-2026)
  3. 3.3 Global Genetic Engineering Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Genetic Engineering Drug Average Price by Company (2021-2026)
  5. 3.5 Global Genetic Engineering Drug Company Ranking (2024-2026)
  6. 3.6 Global Genetic Engineering Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Genetic Engineering Drug Company Product Type and Application
  8. 3.8 Global Genetic Engineering Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Genetic Engineering Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Genetic Engineering Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Genetic Engineering Drug Market by Type
  1. 4.1 Genetic Engineering Drug Type Introduction
  2. 4.1.1 Recombinant Human Insulin
  3. 4.1.2 Recombinant Human Growth Hormone
  4. 4.1.3 Recombinant Human Interferon
  5. 4.1.4 Recombinant Human Erythropoietin
  6. 4.1.5 Monoclonal Antibody
  7. 4.2 Global Genetic Engineering Drug Sales Volume by Type
  8. 4.2.1 Global Genetic Engineering Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Genetic Engineering Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Genetic Engineering Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Genetic Engineering Drug Sales Value by Type
  12. 4.3.1 Global Genetic Engineering Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Genetic Engineering Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Genetic Engineering Drug Sales Value Share by Type (2021-2032)
5 Genetic Engineering Drug Market by Application
  1. 5.1 Genetic Engineering Drug Application Introduction
  2. 5.1.1 Medicine
  3. 5.1.2 Research
  4. 5.1.3 Agriculture
  5. 5.1.4 Industrial
  6. 5.1.5 Other
  7. 5.2 Global Genetic Engineering Drug Sales Volume by Application
  8. 5.2.1 Global Genetic Engineering Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Genetic Engineering Drug Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Genetic Engineering Drug Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Genetic Engineering Drug Sales Value by Application
  12. 5.3.1 Global Genetic Engineering Drug Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Genetic Engineering Drug Sales Value by Application (2021-2032)
  14. 5.3.3 Global Genetic Engineering Drug Sales Value Share by Application (2021-2032)
6 Genetic Engineering Drug Regional Sales and Value Analysis
  1. 6.1 Global Genetic Engineering Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Genetic Engineering Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Genetic Engineering Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Genetic Engineering Drug Sales by Region (2027-2032)
  5. 6.3 Global Genetic Engineering Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Genetic Engineering Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Genetic Engineering Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Genetic Engineering Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Genetic Engineering Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Genetic Engineering Drug Sales Value (2021-2032)
  12. 6.6.2 North America Genetic Engineering Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Genetic Engineering Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Genetic Engineering Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Genetic Engineering Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Genetic Engineering Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Genetic Engineering Drug Sales Value (2021-2032)
  21. 6.9.2 South America Genetic Engineering Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Genetic Engineering Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Genetic Engineering Drug Sales Value Share by Country, 2025 VS 2032
7 Genetic Engineering Drug Country-level Sales and Value Analysis
  1. 7.1 Global Genetic Engineering Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Genetic Engineering Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Genetic Engineering Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Genetic Engineering Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Genetic Engineering Drug Sales by Country (2027-2032)
  6. 7.4 Global Genetic Engineering Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Genetic Engineering Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Genetic Engineering Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Genetic Engineering Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Genetic Engineering Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Genetic Engineering Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao Pharmaceutical
  2. 8.1.1 Tonghua Dongbao Pharmaceutical Company Information
  3. 8.1.2 Tonghua Dongbao Pharmaceutical Business Overview
  4. 8.1.3 Tonghua Dongbao Pharmaceutical Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao Pharmaceutical Genetic Engineering Drug Product Portfolio
  6. 8.1.5 Tonghua Dongbao Pharmaceutical Recent Developments
  7. 8.2 Shenzhen Neptunus Interlong Bio-Technique
  8. 8.2.1 Shenzhen Neptunus Interlong Bio-Technique Company Information
  9. 8.2.2 Shenzhen Neptunus Interlong Bio-Technique Business Overview
  10. 8.2.3 Shenzhen Neptunus Interlong Bio-Technique Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shenzhen Neptunus Interlong Bio-Technique Genetic Engineering Drug Product Portfolio
  12. 8.2.5 Shenzhen Neptunus Interlong Bio-Technique Recent Developments
  13. 8.3 Shanghai Lansheng Guojian Pharmaceutical
  14. 8.3.1 Shanghai Lansheng Guojian Pharmaceutical Company Information
  15. 8.3.2 Shanghai Lansheng Guojian Pharmaceutical Business Overview
  16. 8.3.3 Shanghai Lansheng Guojian Pharmaceutical Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Lansheng Guojian Pharmaceutical Genetic Engineering Drug Product Portfolio
  18. 8.3.5 Shanghai Lansheng Guojian Pharmaceutical Recent Developments
  19. 8.4 Jiangsu Sihuan Bioengineering
  20. 8.4.1 Jiangsu Sihuan Bioengineering Company Information
  21. 8.4.2 Jiangsu Sihuan Bioengineering Business Overview
  22. 8.4.3 Jiangsu Sihuan Bioengineering Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Sihuan Bioengineering Genetic Engineering Drug Product Portfolio
  24. 8.4.5 Jiangsu Sihuan Bioengineering Recent Developments
  25. 8.5 Anhui Anke Biotechnology
  26. 8.5.1 Anhui Anke Biotechnology Company Information
  27. 8.5.2 Anhui Anke Biotechnology Business Overview
  28. 8.5.3 Anhui Anke Biotechnology Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Anhui Anke Biotechnology Genetic Engineering Drug Product Portfolio
  30. 8.5.5 Anhui Anke Biotechnology Recent Developments
  31. 8.6 GeneScience Pharmaceuticals
  32. 8.6.1 GeneScience Pharmaceuticals Company Information
  33. 8.6.2 GeneScience Pharmaceuticals Business Overview
  34. 8.6.3 GeneScience Pharmaceuticals Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GeneScience Pharmaceuticals Genetic Engineering Drug Product Portfolio
  36. 8.6.5 GeneScience Pharmaceuticals Recent Developments
  37. 8.7 Biotech Pharmaceutical
  38. 8.7.1 Biotech Pharmaceutical Company Information
  39. 8.7.2 Biotech Pharmaceutical Business Overview
  40. 8.7.3 Biotech Pharmaceutical Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biotech Pharmaceutical Genetic Engineering Drug Product Portfolio
  42. 8.7.5 Biotech Pharmaceutical Recent Developments
  43. 8.8 Beijing SL Pharmaceutical
  44. 8.8.1 Beijing SL Pharmaceutical Company Information
  45. 8.8.2 Beijing SL Pharmaceutical Business Overview
  46. 8.8.3 Beijing SL Pharmaceutical Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Beijing SL Pharmaceutical Genetic Engineering Drug Product Portfolio
  48. 8.8.5 Beijing SL Pharmaceutical Recent Developments
  49. 8.9 3SBio
  50. 8.9.1 3SBio Company Information
  51. 8.9.2 3SBio Business Overview
  52. 8.9.3 3SBio Genetic Engineering Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 3SBio Genetic Engineering Drug Product Portfolio
  54. 8.9.5 3SBio Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Genetic Engineering Drug Value Chain Analysis
  2. 9.1.1 Genetic Engineering Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Genetic Engineering Drug Sales Mode & Process
  6. 9.2 Genetic Engineering Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Genetic Engineering Drug Distributors
  9. 9.2.3 Genetic Engineering Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst